These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Oh JD; Chase TN Amino Acids; 2002; 23(1-3):133-9. PubMed ID: 12373527 [TBL] [Abstract][Full Text] [Related]
8. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats. Marin C; Jimenez A; Bonastre M; Chase TN; Tolosa E Synapse; 2000 Jun; 36(4):267-74. PubMed ID: 10819904 [TBL] [Abstract][Full Text] [Related]
9. Dopaminergic modulation of striatal function and Parkinson's disease. Zhai S; Shen W; Graves SM; Surmeier DJ J Neural Transm (Vienna); 2019 Apr; 126(4):411-422. PubMed ID: 30937538 [TBL] [Abstract][Full Text] [Related]
13. Alterations in nigral NMDA and GABAA receptor control of the striatal dopamine level after repetitive exposures to nitrogen narcosis. Lavoute C; Weiss M; Rostain JC Exp Neurol; 2008 Jul; 212(1):63-70. PubMed ID: 18452916 [TBL] [Abstract][Full Text] [Related]
15. Striatal glutamate induces retrograde excitotoxicity and neuronal degeneration of intralaminar thalamic nuclei: their potential relevance for Parkinson's disease. Morales I; Sabate M; Rodriguez M Eur J Neurosci; 2013 Jul; 38(1):2172-82. PubMed ID: 23565852 [TBL] [Abstract][Full Text] [Related]
16. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Nash JE; Brotchie JM Mov Disord; 2002 May; 17(3):455-66. PubMed ID: 12112191 [TBL] [Abstract][Full Text] [Related]
17. Regulation of Striatal N-Methyl-D-Aspartate Receptor (NMDAR) Function by Phosphorylation of its Subunits in Parkinsonian Rats. Oh JD Methods Mol Med; 2001; 62():247-53. PubMed ID: 21318780 [TBL] [Abstract][Full Text] [Related]
18. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147 [TBL] [Abstract][Full Text] [Related]
19. Motor response complications and the function of striatal efferent systems. Chase TN; Mouradian MM; Engber TM Neurology; 1993 Dec; 43(12 Suppl 6):S23-7. PubMed ID: 8264907 [TBL] [Abstract][Full Text] [Related]
20. Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications. Mouradian MM; Chase TN Exp Neurol; 1997 Mar; 144(1):51-7. PubMed ID: 9126152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]